Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 9Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Lymphoma 5Lymphoma, B-Cell 3Leukemia 3Recurrence 2Lymphoma, Mantle-Cell 2Solid Tumors 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Indolent Non-Hodgkin's Lymphoma 1Hodgkin Disease 1Hereditary Sensory and Autonomic Neuropathies 1Disease 1Colorectal Neoplasms 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms 1B-cell Malignancies 1

Interventions

Lenalidomide 5Rituximab 4Brentuximab Vedotin 4Vincristine 3Etoposide 3Cyclophosphamide 3romidepsin 2Vorinostat 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Doxorubicin 2Dasatinib 2tislelizumab 1selinexor 1plerixafor 1pembrolizumab 1pegfilgrastim 1parsaclisib 1obinutuzumab 1obatoclax 1monomethyl auristatin E 1liposomal doxorubicin 1ixazomib 1idelalisib 1ibrutinib 1gemcitabine-oxaliplatin regimen 1fludarabine 1etoposide phosphate 1denileukin diftitox 1copanlisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, T-Cell, Peripheral × obinutuzumab × Clear all
NCT01644253 2021-05-20

Phase 1b Safety and Efficacy Study of TRU-016

Aptevo Therapeutics

Phase 1 Terminated
87 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡